Skip to content
10-K

Annual Report

Transcode Therapeutics, Inc. RNAZ

0001104659-26-043810

← back to feed
Filed
Apr 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Apr 3, 2026 916.97K sh
Shares Diluted FY 2025 · Dec 31, 2025 689.71K sh
Shares Diluted restated FY 2025 · Dec 31, 2024 12.56K sh
Capex FY 2025 · Dec 31, 2025 $6.66K
Capex FY 2025 · Dec 31, 2024 $21.76K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$19.52M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$13.34M
Cash And Equivalents FY 2025 · Dec 31, 2025 $17.81M
Cash And Equivalents FY 2025 · Dec 31, 2024 $5.81M
Stockholders Equity FY 2025 · Dec 31, 2025 $10.34M
Stockholders Equity FY 2025 · Dec 31, 2024 −$2.02M
Stockholders Equity FY 2025 · Dec 31, 2023 $1.64M
Current Liabilities FY 2025 · Dec 31, 2025 $3.49M
Current Liabilities FY 2025 · Dec 31, 2024 $2.77M
Total Liabilities FY 2025 · Dec 31, 2025 $10.52M
Total Liabilities FY 2025 · Dec 31, 2024 $9.31M
Current Assets FY 2025 · Dec 31, 2025 $21.98M
Current Assets FY 2025 · Dec 31, 2024 $7.09M
Total Assets FY 2025 · Dec 31, 2025 $162.4M
Total Assets FY 2025 · Dec 31, 2024 $7.29M
Eps Diluted FY 2025 · Dec 31, 2025 −$52.59
Eps Diluted restated FY 2025 · Dec 31, 2024 −$1,336.63
Eps Basic FY 2025 · Dec 31, 2025 −$52.59
Eps Basic restated FY 2025 · Dec 31, 2024 −$1,336.63
Sga Expense FY 2025 · Dec 31, 2025 $5.77M
Sga Expense FY 2025 · Dec 31, 2024 $5.95M
Rd Expense FY 2025 · Dec 31, 2025 $13.42M
Rd Expense FY 2025 · Dec 31, 2024 $9.71M
Net Income FY 2025 · Dec 31, 2025 −$34.66M
Net Income FY 2025 · Dec 31, 2024 −$16.75M
Operating Income FY 2025 · Dec 31, 2025 −$27.98M
Operating Income FY 2025 · Dec 31, 2024 −$15.66M